RDInvesting Provides Investors with Free In-Depth Equity Reports on CBI, DDS, NPSP and TLAB
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Chicago Bridge & Iron Company N.V. (NYSE: CBI) closed at $61.30 a share Friday. The stock traded between $60.70 and $61.38 on volume of 917,579 shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” and currently have a $74.00 price target on the stock. Shares of Chicago Bridge & Iron have gained approximately 32.25 percent year-to-date.
Find out more about Chicago Bridge & Iron including full access to the free equity report at:
www.RDInvesting.com/CBI
Dillard's, Inc. (NYSE: DDS) shares decreased 0.46 percent to close at $83.97 a share Friday. The stock traded between $60.70 and $61.38 on volume of 917,579 shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” and currently have a $93.00 price target on the stock.
Find out more about Dillard's including full access to the free equity report at:
www.RDInvesting.com/DDS
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) shares spiked 4.60 percent to close at $17.51 a share Friday. The stock traded between $16.70 and $17.66 on volume of 1.71 million shares traded. Analysts at Zacks have recently upgraded the company’s rating to “outperform” and currently have an $18.30 price target on the stock. Shares of NPS Pharmaceuticals have gained approximately 92.4 percent year-to-date.
Find out more about NPS Pharmaceuticals including full access to the free equity report at:
www.RDInvesting.com/NPSP
Tellabs, Inc. (NASDAQ: TLAB) shares gained 0.46 percent to close at $2.17 a share Friday. The stock traded between $2.15 and $2.17 on volume of 968,060 shares traded. Analysts at Zacks have recently downgraded the company’s rating to “underperform” and currently have a $2.00 price target on the stock. Shares of NPS Pharmaceuticals have gained approximately 92.4 percent year-to-date.
Find out more about Tellabs including full access to the free equity report at:
www.RDInvesting.com/TLAB
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Research Driven Investing
info@rdinvesting.com